7-103297487-T-G
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_004279.3(PMPCB):āc.28T>Gā(p.Leu10Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000274 in 1,568,758 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_004279.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PMPCB | NM_004279.3 | c.28T>G | p.Leu10Val | missense_variant | 1/13 | ENST00000249269.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PMPCB | ENST00000249269.9 | c.28T>G | p.Leu10Val | missense_variant | 1/13 | 1 | NM_004279.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000283 AC: 43AN: 152118Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000336 AC: 72AN: 214108Hom.: 0 AF XY: 0.000341 AC XY: 39AN XY: 114494
GnomAD4 exome AF: 0.000273 AC: 387AN: 1416522Hom.: 0 Cov.: 31 AF XY: 0.000301 AC XY: 211AN XY: 700032
GnomAD4 genome AF: 0.000282 AC: 43AN: 152236Hom.: 0 Cov.: 33 AF XY: 0.000282 AC XY: 21AN XY: 74442
ClinVar
Submissions by phenotype
Multiple mitochondrial dysfunctions syndrome 6 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 14, 2019 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Aug 28, 2019 | A heterozygous missense variant was identified, NM_004279.2(PMPCB):c.28T>G in exon 1 of 13 of the PMPCB gene. This substitution is predicted to create a minor amino acid change from leucine to valine at position 10 of the protein, NP_004270.2(PMPCB):p.(Leu10Val). The leucine at this position has low conservation (100 vertebrates, UCSC). It is located within the mitochondrial targeting sequence. In silico software predicts this variant to be benign (Polyphen, SIFT, CADD, Mutation Taster). The variant is present in the gnomAD population database at a frequency of 0.03% (77 heterozygotes, 0 homozygotes). It has not been previously reported in clinical cases. Based on information available at the time of curation, this variant has been classified as a VARIANT of UNCERTAIN SIGNIFICANCE (VUS). - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 01, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 10 of the PMPCB protein (p.Leu10Val). This variant is present in population databases (rs77305684, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with PMPCB-related conditions. ClinVar contains an entry for this variant (Variation ID: 1030758). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 30, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at